Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amazing Momentum!!!!
Ask is .50 now
Are we gearing up for good 3rd quarter news? What is the latest run from? Good Luck
SYMBA @ .045!
;)
Congrats Finless!
;)
GLTU
Looking great today! Glad I held on.
SYMBA looking good @ .03!
;)
I'm long in SYMBA! Big accumulation lately!
GLTU!
;)
Hold on for earnings report or get out now?
SYMBA NEWS!
Symbollon Pharmaceuticals Announces Agreement With Integra Labs, Inc. for Distribution of IoGen(TM)
FRAMINGHAM, MA, Jul 07, 2009 (MARKETWIRE via COMTEX) -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) announces the company has entered into a distribution agreement with Integra Labs, Inc. for the distribution of their breast health formulation IoGen(TM).
On June 30, 2009, Symbollon Pharmaceuticals, Inc. signed a distribution agreement with Integra Labs, Inc. granting Integra the exclusive right to distribute Symbollon's dietary supplement, IoGen(TM), in countries allowing over-the-counter sales of the product. Under the agreement, Integra will assume all manufacturing, sales and marketing responsibilities for the product. In addition, Integra will purchase Symbollon's existing inventory of IoGen(TM). Integra will pay Symbollon a royalty on all sales of IoGen. The initial term of the agreement is for five years, subject to the achievement of certain milestones and minimum sales requirements. Pursuant to the agreement, the parties intend to identify other OTC product opportunities utilizing Symbollon's molecular iodine technology which would also be distributed by Integra.
"We are very excited to have joined forces with Integra to expand the market for IoGen(TM)," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. "We are confident Integra's sales and marketing acumen will help to substantially increase the sales of IoGen(TM). We look forward to developing with Integra other OTC products based on the company's molecular iodine technology which will target other significant market opportunities."
Martha Herrod, President of Integra Labs, Inc., stated that "We are proud to be the exclusive distributor of IoGen(TM) and are anxious to start generating sales. Our existing strategic relationships and experienced sales force intend to market IoGen(TM) to success. We also look forward to several potential joint ventures in the future."
About Symbollon Pharmaceuticals, Inc.
Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is a specialty pharmaceutical company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobial uses. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.
About Integra Labs, Inc.
Integra Labs, Inc. is an online marketing and media company engaged in the promotion of alternative health remedies and other healthy living solutions. Integra partners with life science based companies to develop, produce and market products backed by science and efficacy catering to market segments that provide a net positive benefit with a long-term customer lifecycle. Integra's marketing activities are primarily in the $5 billion direct-to-consumer supplement sales via the World Wide Web, targeted towards active consumers between the ages of 18 and 55. Integra believes that the quality of its products and effectiveness of its marketing network are the strengths behind its success. For more information go to: www.Integralabs.com.
Forward-Looking Statement
This news release contains statements by Symbollon that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to increase sales of IoGen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) Symbollon will be able to enter into new strategic alternatives, including sale of the Company or its assets, (iv) management and the Board of Directors will be able to maximize shareholder value by leveraging Symbollon's proprietary technology, and (v) such other factors as may be disclosed from time-to-time in Symbollon's reports as filed with the Securities and Exchange Commission.
Contact:
Paul C. Desjourdy
President and CEO
Symbollon Pharmaceuticals, Inc.
(508) 620-7676, x202
http://www.symbollon.com
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=symba
"Symbollon is poised for explosive growth. Symbollon was founded in 1986 and had its initial public offering in 1993. Symbollon is leading the world in the development of products based on its molecular iodine technology. With product opportunities in two large market segments: women’s healthcare and antimicrobial applications."
http://www.symbollon.com/
That makes me dizzy! The Six Flags effect, lol!
yikes
tiny buy drops it down 58%
sheesh
SYMBA Golden Cross NOW!
;)
symba looks jiggy
SYMBA was $1.0 on 2008!
;)
SYMBA 10k Filling!
http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6510842
WE LOVE IT!!!
;)
WE LOVE IT!!!
;)
Another nice Low OS mover E!
CARLITO!!! WELCOME TO SYMBA!!!!
;)
.01 x.012
Y high = .9 , so lot of roommmmmmmmm
SYMBA only 16m o/s!!
;)
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
108
|
Created
|
02/20/08
|
Type
|
Free
|
Moderators |
Symbollon Pharmaceuticals, Inc.
37 Loring Drive
Framingham, MA 01702
Outstanding Shares
16,473,340 as of Aug 13, 2008
Massive Insider activity
http://www.nasdaq.com/asp/quotes_sec.asp?mode=&kind=&timeframe=&intraday=&charttype=&splits=&earnings=&movingaverage=&lowerstudy=&comparison=&index=&symbol=SYMBA&symbol=PP&symbol=DNDN&symbol=PRAN&symbol=ALSE&symbol=EPCT&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&FormType=&mkttype=&pathname=&page=filings&selected=SYMBA
http://finance.yahoo.com/q/it?s=SYMBA.OB
Results of Pivotal Study to Be Published in March 2008
Symbollon Pharmaceuticals Completes Phase III Pivotal Trial for IoGen
Thursday February 7, 12:28 pm ET
FRAMINGHAM, MA--(MARKET WIRE)--Feb 7, 2008 -- Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) today announced the completion of its IoGen(TM) Phase III pivotal trial. The study, conducted by physicians throughout the U.S., is designed to evaluate the effectiveness of IoGen, a treatment which may be the first FDA-approved, non-hormonal therapy for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD).
ADVERTISEMENT
With the last of the 140 patients randomized in the trial having completed the dosing stage of the study, Symbollon is focused on closing the database. The Company anticipates that the database will be locked in March 2008 and plans to release the trial results at that time.
"We believe that the release of the Phase III data will be the most significant milestone in Symbollon's history," said Paul Desjourdy, President and CEO of Symbollon Pharmaceuticals. "Prior to this study, we had collected clinical data on approximately 3,000 women with FBD. The current Phase III study will help determine whether IoGen can be commercialized as the first non-hormonal drug approved to treat women suffering from FBD."
Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its molecular iodine technology. Symbollon is conducting a Phase III clinical trial evaluating IoGen as a potential treatment for moderate to severe periodic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD). FBD is a condition that affects approximately 20 to 33 million women in the U.S., and there are approximately 7 to 13 million women suffering from clinical periodic mastalgia. The Company believes IoGen also may be useful in treating and/or preventing endometriosis, ovarian cysts, and premenopausal breast cancer. Symbollon is also in preclinical development of antimicrobial products based on the same molecular iodine technology, and intends to investigate the potential effectiveness of its technology in applications such as dermatology, oral care, upper respiratory tract conditions, urinary tract infection and wound care. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.
Symbollon Pharmaceuticals, Inc. (OTC BB: SYMBA) is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its molecular iodine technology. Symbollon is conducting a Phase III clinical trial evaluating IoGen (I2) for pain/tenderness associated with fibrocystic breast disease (FBD) and/or with potential to treat cancer. Enrollment for the study closes at the end of June 2007 and results are expected to be published in Q1 2008.
The Company believes IoGen has the ability to eliminate excess cell growth in female reproductive tissue, including the breast, ovaries and uterus. Other indications for IoGen include the treatment and/or preventing endometriosis, ovarian cysts, and pre-menopausal breast cancer. The company has 25 patents in the US, with foreign counterparts, covering the technology.
While there are several breast cancer drugs on the m arket, all available hormonal therapies have significant adverse effects. In contrast, IoGen is a non-hormonal treatment that allows for safe long-term use with little or no sides effects. In fact, in the last Phase II study of IoGen there were no drug-related adverse events reported.
“We believe that the current research provides substantive support for the initiation of human clinical studies on the use of molecular iodine as a treatment for breast cancer,” stated Paul Desjourdy, President and CEO of Symbollon Pharmaceuticals, Inc. “The possibility that IoGen may be used as a treatment for breast cancer makes it all the more important that Symbollon expedite the commercialization time line for IoGen.”
Recent Developments
Symbollon announced that it would seek regulatory guidance in commercialization of IoGen in Europe. The company targeted The United Kingdom, Germany and Sweden. Symbollon has met with representatives of these regulatory bodies and has received guidance and comments, which should accelerate the commercialization of IoGen in Europe. The Company has also met with Canadian regulators and has received consistent comments that will allow for a regulatory filing after completion of the planned clinical trials.
In addition, Symbollon Pharmaceuticals announced that it is closing the enrollment of its IoGen Phase III pivotal pain study in June 2007 and anticipates announcing the study results in first quarter of 2008. The ongoing IoGen study has over 25 active sites across the United States. The study has been registered with FDA under the Protocol Registration System at ClinicalTrials.gov.
About IoGen
Symbollon has initiated a pivotal Phase III clinical trial evaluating IoGen as a potential treatment for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD).
FBD is characterized by benign excess cell growth (fibrosis) and mastalgia. Benign fibrosis is a chronic condition that affects approximately 20 million to 33 million women in the U.S. In addition, there are approximately 7 million to 13 million women suffering from clinical cyclic mastalgia.
Product Focus
Symbollon’s free molecular iodine technology has potential uses in a number of application areas, which can be broadly grouped into two areas: women’s healthcare (as mentioned above) and antimicrobial applications.
Symbollon is in preclinical development of antimicrobial and intends to investigate the potential effectiveness of its technology in applications such as dermatology, oral care, upper respiratory tract conditions, urinary tract infection and wound care.
Symbollon has commercialized one animal drug, a bovine teat sanitizer, for use on the dairy farms to disinfect cow’s udders. The product is a powdered concentrate that delivers high levels of molecular iodine for fast and effective elimination of all pathogens.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |